Adhera Therapeutics Inc.

As of September 30, 2023, Adhera Therapeutics Inc. carries a market capitalization of 155,067.36, placing it among publicly traded companies globally. Its enterprise value stands at 10.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2023, Adhera Therapeutics Inc. has 5.17M shares outstanding.

These figures are as of September 30, 2023.

As of September 30, 2023, Adhera Therapeutics Inc. maintains a current ratio of 0.00, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -41.15, indicating conservative leverage, while an interest coverage ratio of -0.40 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2023. Return on assets (ROA) is negative at -2,989.81, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 7, 2026, Adhera Therapeutics Inc.'s stock has gained approximately 0.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.01.

Over the twelve months ended September 30, 2023, Adhera Therapeutics Inc. generated - - in revenue and converted that into -4.49M in net income, yielding earnings per share of -0.15. EBITDA reached -1.28M, while operating income came in at -1.28M.

As of September 30, 2023, Adhera Therapeutics Inc. holds 32,388.00 in cash and equivalents against 10.83M in total debt, resulting in a net debt position of 10.80M. Total book value stands at -26.32M, with working capital of -26.32M providing operational flexibility.

Adhera Therapeutics Inc. produced -808,155.00 in operating cash flow over the twelve months ended September 30, 2023.

These figures cover the twelve months ended September 30, 2023. The dividend payout ratio of 1.26 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -98.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -456.44, meaning Adhera Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Adhera Therapeutics Inc.'s most recent stock split took place on October 6, 2022 with a 20:1 split ratio.

As of September 30, 2023, Adhera Therapeutics Inc. has an Altman Z-Score of -2,717.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.